GlassScriptPhysician profile
Suneal Kumar Agarwal
NPI 1720242324
$35,504.60
in general payments reported to CMS, 2019-2025
46 companies · $2,566 in 2025
The $2,566 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,304 · 2021: $4,517 · 2022: $2,958 · 2023: $2,620 · 2024: $3,246 · 2025: $2,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,410 · Education: $22.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,409.95 |
| Education | $22.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13,281.81 | 2019-2025 | Xifaxan, Trulance |
| Ferring Pharmaceuticals INC. | $6,292.42 | 2020-2021 | |
| Abbvie INC. | $5,413.43 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Redhill Biopharma INC. | $2,850.00 | 2020 | |
| Conmed Corporation | $1,092.50 | 2022-2025 | Conmed Generators, Conmed Biliary, Conmed Hemostasis |
| Takeda Pharmaceuticals U.S.A., INC. | $945.19 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Boston Scientific Corporation | $614.07 | 2023-2025 | Overstitch Endoscopic Suturing System, Orise, Exalt Model D |
| Janssen Biotech, INC. | $451.42 | 2021-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $438.80 | 2023-2025 | Voquezna |
| Steris Corporation | $422.43 | 2022 | |
| Genzyme Corporation | $277.68 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $258.43 | 2021-2022 | |
| 3-D Matrix, INC. | $248.98 | 2024 | |
| Allergan, INC. | $193.80 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $184.69 | 2024-2025 | Dupixent |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneal Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.